Aktuellt
SENASTE
Redeye initiates coverage of OncoZenge, a Swedish biotech company offering an innovative solution to the USD1.6bn oral mucositis treatment market. Bolstered by a strong ownership, a newly signed commercial partnership, and a de-risked pathway to the market, we see ample upside potential.
LÄS MER
